Q-omics provides the consensus-scored FRRS1L profile across patient tissues and cancer cell-line models. FRRS1L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FRRS1L is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, FRRS1L RNA expression shows 17,761 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where FRRS1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRRS1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRRS1L survival associations across molecular data types. FRRS1L RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRRS1L RNA expression–survival associations across cancer types. High FRRS1L expression shows unfavorable associations in UVM, SKCM and KIRC, but favorable associations in BRCA, LGG and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FRRS1L RNA expression.
This table summarizes FRRS1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FRRS1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRRS1L shows lower tumor expression in KIRC, COAD, STAD, UCEC, BRCA and THCA. The KIRC box plot shows higher FRRS1L RNA expression in normal versus tumor tissue (log2 FC = −0.139, t-test p < 0.001).
This table shows molecular features associated with FRRS1L in patient tissues and cancer cell lines. In patient samples, FRRS1L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRRS1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
